EP19 Renal sarcoidosis associated with certolizumab pegol treatment for psoriatic arthritis: a case report
نویسندگان
چکیده
منابع مشابه
Certolizumab pegol for the treatment of psoriatic arthritis.
Certolizumab pegol (CZP) is a TNF-α inhibitor approved for the treatment of psoriatic arthritis in 38 countries, including many European countries and the USA. It is a pegylated humanized anti-TNF-α antigen-binding fragment, administered subcutaneously. As other TNF-α antibodies, CZP binds to and neutralizes both soluble and membrane TNF-α. In contrast to whole antibodies and etanercept, CZP do...
متن کاملPsoriatic arthritis of temporomandibular joint with ankylosis :a case report
Psoriasis is a chronic inflammatory proliferative disorder of the skin that appears in many different forms and affect different parts of the body including the nails and joints. It may affect the quality of life by causing psychosocial stress. Psoriatic arthritis is a seronegative spondyloarthropathy with involvement of axial and peripheral joints. Involvement of temporomo andibular joint is a...
متن کاملCertolizumab pegol for the treatment of rheumatoid arthritis.
INTRODUCTION Improved understanding of the pathogenesis of rheumatoid arthritis (RA), and subsequent development of targeted therapies, have greatly advanced the management of this chronic inflammatory disease. The aim of treatment is a state of clinical remission. Certolizumab pegol (CZP) is a novel pegylated TNF alpha inhibitor (TNFi) therapy and is the focus of this review. AREAS COVERED C...
متن کاملCorrection to: Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
In the original publication, part Fig. 3b and c were interchanged. The correct versions are given below.
متن کاملCertolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data
INTRODUCTION We present the results of real-life tests conducted in adults affected by psoriatic arthritis (PsA) with mild cutaneous involvement to evaluate the efficacy of certolizumab pegol (CZP), an anti-tumor necrosis factor-alpha agent approved in Europe for the treatment of rheumatoid arthritis and PsA. METHODS Assessments included an evaluation of the Psoriasis Area and Severity Index ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Rheumatology Advances in Practice
سال: 2020
ISSN: 2514-1775
DOI: 10.1093/rap/rkaa052.018